AnaptysBio Company Insiders

ANAB Stock  USD 17.42  0.62  3.44%   
About 79 percent of AnaptysBio's insiders are selling. The analysis of the overall insider sentiment regarding AnaptysBio suggests that quite a large number of insiders are terrified. AnaptysBio employs about 117 people. The company is managed by 13 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 9.0 employees per reported executive.
Eric Loumeau  Executive
General Counsel

AnaptysBio's Insider Buying Vs Selling

21

 
Selling
 
Buying

Latest Trades

2025-01-02Ecor1 Capital, LlcAcquired 6646 @ 12.95View
2024-12-30Ecor1 Capital, LlcAcquired 65184 @ 12.92View
2024-09-23Paul F LizzulDisposed 1500 @ 38.67View
2024-09-16Eric J LoumeauDisposed 8720 @ 39.82View
2024-08-14Ecor1 Capital, LlcAcquired 273972 @ 36.5View
2024-07-18Paul F LizzulDisposed 1500 @ 35View
2024-07-15Hollings RentonDisposed 10000 @ 30.64View
2024-06-21Dennis M FentonDisposed 1950 @ 23.17View
2024-06-18Hollings RentonDisposed 1950 @ 23.16View
2024-05-22Dennis MulroyDisposed 1500 @ 23.72View
2024-03-25Daniel FagaDisposed 3000 @ 21.42View
2024-03-22Daniel FagaDisposed 145940 @ 22.78View
2024-02-16Eric J LoumeauDisposed 5000 @ 25View
2024-01-30Dennis MulroyDisposed 3065 @ 23.63View
Monitoring AnaptysBio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

AnaptysBio's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AnaptysBio's future performance. Based on our forecasts, it is anticipated that AnaptysBio will maintain a workforce of about 120 employees by March 2025.
 
Covid

AnaptysBio Management Team Effectiveness

The company has return on total asset (ROA) of (0.1785) % which means that it has lost $0.1785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6182) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, AnaptysBio's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 11 M, whereas Total Assets are forecasted to decline to about 354.3 M.
As of January 31, 2025, Common Stock Shares Outstanding is expected to decline to about 21 M. The current year's Net Loss is expected to grow to about (110.1 M)

AnaptysBio Workforce Comparison

AnaptysBio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,250. AnaptysBio holds roughly 117 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.9) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.76.

AnaptysBio Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AnaptysBio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.8333
33
18
 1,040,262 
 174,625 
2024-12-01
1.5
3
2
 88,452 
 20,000 
2024-09-01
0.7143
15
21
 573,272 
 91,240 
2024-06-01
0.7
7
10
 26,069 
 28,235 
2024-03-01
1.9286
27
14
 1,106,535 
 558,136 
2023-09-01
0.875
7
8
 37,846 
 32,105 
2022-09-01
3.0
3
1
 36,000 
 523.00 
2022-06-01
2.0
8
4
 1,388,974 
 1,340,120 
2021-12-01
0.8667
13
15
 131,381 
 223,231 
2021-09-01
1.0
1
1
 10,000 
 10,000 
2021-06-01
7.0
7
1
 378,800 
 10,000 
2021-03-01
8.5
17
2
 3,691,784 
 20,000 
2020-12-01
0.6667
2
3
 48,958 
 1,416,747 
2020-03-01
4.0
8
2
 86,000 
 20,000 
2019-12-01
3.0
6
2
 535,802 
 56,202 
2019-09-01
3.0
3
1
 25,768 
 0.00 
2019-06-01
0.2
2
10
 20,060 
 52,548 
2019-03-01
1.5714
11
7
 200,075 
 212,150 
2018-12-01
0.2222
6
27
 169,363 
 466,224 
2018-09-01
1.0
4
4
 190,493 
 150,493 
2018-06-01
0.25
3
12
 355,306 
 4,472,452 
2018-03-01
13.0
13
1
 183,990 
 16,483 
2017-09-01
0.2727
3
11
 76,305 
 1,533,927 
2017-03-01
0.6087
42
69
 14,848,215 
 18,629,677 

AnaptysBio Notable Stakeholders

An AnaptysBio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AnaptysBio often face trade-offs trying to please all of them. AnaptysBio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AnaptysBio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Martin DahlSenior ResearchProfile
Monique SilvaSenior AffairsProfile
James MDAdvisorProfile
Beth MuellerSenior ResourcesProfile
Priya RainaSenior OperationsProfile
FAAD MBAChief OfficerProfile
Daniel FagaInterim DirectorProfile
MSc MBAAdvisoryProfile
Dennis MulroyChief OfficerProfile
Douglas MBASenior CMCProfile
Eric LoumeauGeneral CounselProfile
Benjamin StoneChief OfficerProfile
MSc MDSenior DevelopmentProfile

About AnaptysBio Management Performance

The success or failure of an entity such as AnaptysBio often depends on how effective the management is. AnaptysBio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AnaptysBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AnaptysBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.33)(0.34)
Return On Capital Employed(0.36)(0.37)
Return On Assets(0.33)(0.34)
Return On Equity(1.67)(1.75)
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.

AnaptysBio Workforce Analysis

Traditionally, organizations such as AnaptysBio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AnaptysBio within its industry.

AnaptysBio Manpower Efficiency

Return on AnaptysBio Manpower

Revenue Per Employee146.6K
Revenue Per Executive1.3M
Net Loss Per Employee1.4M
Net Loss Per Executive12.6M
Working Capital Per Employee3.2M
Working Capital Per Executive28.4M

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine